{"nctId":"NCT01598831","briefTitle":"Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy","startDateStruct":{"date":"2012-10-29","type":"ACTUAL"},"conditions":["Severe Sepsis","Coagulopathy"],"count":816,"armGroups":[{"label":"ART-123","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ART-123"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"ART-123","otherNames":["human recombinant thrombomodulin","thrombomodulin alfa"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject must be receiving treatment in an ICU, or in an acute care setting (e.g., ER, RR)\n* Clinical objective evidence of bacterial infection and a known site of infection.\n* Cardiovascular dysfunction or Respiratory Failure due to sepsis.\n* Coagulopathy characterized by an INR \\>1.40 without other known causes.\n\nExclusion Criteria:\n\n* Subject or Authorized Representative is unable to provide informed consent.\n* Subject is pregnant or breastfeeding or intends to get pregnant within 28 days of enrolling into the study.\n* Subject is of childbearing potential and does not have a negative pregnancy test.\n* Subject is \\< 18 years of age.\n* Subject has a known allergy to ART-123 or any components of the drug product.\n* Subject is unwilling to allow transfusion of blood or blood products.\n* Subject has an advance directive to withhold life-sustaining treatment.\n* Subject has had previous treatment with ART-123.\n* Body weight â‰¥ 175 kg.\n* Platelets \\< 30,000/ mm3 for any reason, PT prolongation or thrombocytopenia that is not due to sepsis.\n* Any surgery that is potentially hemorrhagic (e.g. intra-thoracic, intra-abdominal or non-traumatic orthopedic surgery of the femur or pelvis) that is completed within 12 hours prior to first dose of study drug, or ongoing impairment of hemostasis as a result of one of these procedures\n* History of head trauma, spinal trauma, or other acute trauma with an increased risk of bleeding within 3 months prior to consent.\n* Cerebral Vascular Accident (CVA) within 3 months prior to consent.\n* Any history of intracerebral arteriovenous malformation (AVM), cerebral aneurysm, or mass lesions of the central nervous system.\n* History of congenital bleeding diathesesor anatomical anomaly that predisposes to hemorrhage (e.g. hemophilia, hereditary hemorrhagic telangiectasia).\n* Significant gastrointestinal bleeding within 6 weeks prior to consent.\n* Subject is diagnosed with a known medical condition associated with a hypercoagulable state.\n* Child-Pugh score of 10-15 (Class C)\n* Portosystemic hypertension or known history of bleeding esophageal varices.\n* History of solid organ, allogeneic bone marrow, or stem cell transplantation within the 6 months prior to consent.\n* Acute pancreatitis where infection has not been documented by a positive blood or abdominal fluid culture or gram stain consistent with bacterial infection.\n* Subjects with renal dysfunction defined as (a) Chronic renal failure requiring renal replacement therapy (RRT), or (b) Acute renal failure with onset of oliguria (urine output \\< 0.3 ml/kg/hr) \\> 48 hours prior to first dose of study drug whether receiving RRT or not\n* Use of anticoagulants, antiplatelet agents, antithrombotics and thrombolytics within the 72 hours prior to first does of study drug.\n* Life expectancy \\< 90 days.\n* Current use of any chemotherapy agent likely to cause myeloablation (severe or complete depletion of bone marrow).\n* Participation in another research study involving an investigational agent within 30 days prior to consent or projected study participation during the 28 days post study randomization.\n* Confirmed or suspected endocarditis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With 28-Day All-cause Mortality","description":"28-Day All-cause Mortality","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"119","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With On-Treatment Serious Major Bleeding Events","description":"On-treatment Serious Major Bleeding Events collected as Serious Adverse Events and defined as: any intracranial hemorrhage, any life-threatening bleeding, any bleeding event classified as serious by the Investigator (e.g., resulting in permanent morbidity), or any bleeding that required the administration of 1440 ml (typically 6 units) of packed red cells over two consecutive days. (Investigator assessment for seriousness criteria.)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Follow up All-cause Mortality at 3 Months","description":"Follow up all-cause mortality at 3 months","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null},{"groupId":"OG001","value":"136","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Event Free and Alive Days to Measure Resolution of Organ Dysfunction","description":"Resolution of organ dysfunction as measured through day 28 by shock free, ventilator free, dialysis free plus alive days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6","spread":"10.50"},{"groupId":"OG001","value":"17.6","spread":"10.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.8","spread":"11.75"},{"groupId":"OG001","value":"14.5","spread":"11.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.2","spread":"11.05"},{"groupId":"OG001","value":"19.6","spread":"11.21"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Anti-drug Antibodies","description":"Presence of Anti-drug antibodies up to 18 months","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"POST_HOC","title":"Day 28 Mortality in Subjects With INR > 1.4 at Baseline and PLT > 30K at Baseline","description":"Post-Hoc analysis of Day 28 Mortality in Subjects with INR \\> 1.4 at Baseline and PLT \\> 30K at Baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"105","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":206,"n":396},"commonTop":["Anaemia","Hypokalaemia","Atrial fibrillation","Thrombocytopenia","Hypophosphataemia"]}}}